EUVIMEDEUVIMED entdecken
Open Access

Impact of China’s National Volume-Based Procurement Policy on the Affordability and Utilization of Tyrosine Kinase Inhibitors for Childhood Leukemia

Yiran Li, Yao Xie, Fanyu Liu, Yongyi Wu, Siyu Liu, Xiao Han, Xiaohan Fan, Zhao Yang, Bin Jiang

Health Data Science · 01.01.2026 · 6

DOI: 10.34133/hds.0453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Data Science, online erschienen am 04.05.2026. Verfasst von Yiran Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Economics, University of Chinese Academy of Social Sciences, Beijing, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Innovative Research Group Project of the National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Leukemia is the most common childhood cancer. While tyrosine kinase inhibitors (TKIs) improve survival, they impose substantial economic burdens. This study evaluates the impact of China’s National Volume-Based Procurement (NVBP) policy on the affordability and usage of TKIs in children’s hospitals.

Method

We analyzed procurement data for imatinib, nilotinib, and dasatinib from children’s hospitals between January 2019 and December 2020. An interrupted time series model was employed to assess 3 outcomes: affordability (monthly cost-to-wage ratio), procurement volume (defined daily doses), and expenditure. Stratified analyses were conducted based on bid-winning status and generic versus originator drug types.

Results

The NVBP policy effectively influenced some TKIs. For imatinib, which is included in the NVBP policy, imatinib procurement volume and expenditure showed significant upward trends ( P < 0.05 and P < 0.01, respectively). Notably, the volume for bid-winning generics increased significantly ( P < 0.05) upon policy implementation. The expenditure structure of TKI drugs underwent significant changes due to the policy, with a gradual increase in the proportion of expenditures for bid-winning generic drugs.

Conclusion

The NVBP policy effectively improved TKI affordability and promoted the substitution of bid-winning generics in pediatric leukemia treatment. These changes optimized the medication expenditure structure, helping to alleviate the economic burden on families, although further policy refinements for pediatric-specific needs are warranted.

Autor:innen und Institutionen

  • School of Economics, University of Chinese Academy of Social Sciences, Beijing, China.
  • Pediatric Department of Peking University First Hospital, Beijing, China.
  • Institute of New Structural Economics, Peking University, Beijing, China.
  • School of Public Health, Kunming Medical University, Kunming, Yunnan Province, China.
  • Shanxi Medical University, Jinzhong, Shanxi Province, China.
  • School of Public Health, Shanghai Jiaotong University, Shanghai, China.

Förderung

  • Innovative Research Group Project of the National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Li, Y., Xie, Y., Liu, F., Wu, Y., Liu, S., Han, X., Fan, X., Yang, Z., & Jiang, B. (2026). Impact of China’s National Volume-Based Procurement Policy on the Affordability and Utilization of Tyrosine Kinase Inhibitors for Childhood Leukemia. Health Data Science, 6. https://doi.org/10.34133/hds.0453

Vancouver

Li Y, Xie Y, Liu F, Wu Y, Liu S, Han X, et al. Impact of China’s National Volume-Based Procurement Policy on the Affordability and Utilization of Tyrosine Kinase Inhibitors for Childhood Leukemia. Health Data Science. 2026;6. doi:10.34133/hds.0453

BibTeX
@article{Li2026,
  author = {Li, Yiran and Xie, Yao and Liu, Fanyu and Wu, Yongyi and Liu, Siyu and Han, Xiao and Fan, Xiaohan and Yang, Zhao and Jiang, Bin},
  title = {Impact of China’s National Volume-Based Procurement Policy on the Affordability and Utilization of Tyrosine Kinase Inhibitors for Childhood Leukemia},
  journal = {Health Data Science},
  year = {2026},
  volume = {6},
  doi = {10.34133/hds.0453}
}
Kostenlos starten →